Efforts to control drug prices seemed on a glide path earlier this year after gaining traction at the White House and in Congress. But prospects today look less certain and highly controversial.
A draft plan spearheaded by House Speaker Nancy Pelosi would allow the federal government for the first time to negotiate prices for 250 drugs for Medicare and apply those prices to all payers, including employers and insurers.
Despite what New York Mayor Bill de Blasio claimed during the first night of the presidential debates, universal health care in the Big Apple is still in the seeding stage.
Supporters of the rule say it would strengthen health care professionals’ freedom of conscience, but opponents say it “empowers bad actors to be bad actors.”
In March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.
It’s as shady as it sounds.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate Finance Committee hearing could produce fireworks over prices, R&D costs and executive compensation.
The recent declaration by President Donald Trump that taming unexpected medical bills would be a top priority for his administration echoed through the halls of Congress.
Key House and Senate committees kick off hearings on drug prices, and patients’ families weigh in with tragic stories.